Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early-Stage Breast Cancer Detection in Breast Milk

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ortiz, Carolina|||0000-0002-5523-829X
  • Matito, Judit|||0000-0001-7560-7737
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Suñol Camas, Anna
  • Martín, Ágatha|||0000-0003-4818-6433
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Miranda, Ignacio|||0000-0002-4813-5946
  • Morales-Comas, Clara|||0000-0001-6771-6749
  • Carrasco, Estela|||0000-0003-1964-7675
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Peg, Vicente|||0000-0002-5203-6166
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • González Medina, Alberto, 1990-|||0000-0002-2819-9053
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Arévalo, Silvia|||0000-0001-8169-1322
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Tabernero, Josep|||0000-0002-2495-8139
  • Vivancos, Ana|||0000-0003-2888-6512
  • Sansó, Miriam|||0000-0001-7155-4041
The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis. For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  • Nadal Serrano, Mercedes
  • Morancho Armisen, Beatriz
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Luque García, Antonio
  • Espinosa Bravo, Martin
  • Peg Camara, Vicente
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
T-DM1; Conjugat anticòs-fàrmac; Càncer de mama, T-DM1; Conjugado anticuerpo-fármaco; Cáncer de mama, T-DM1; Antibody-drug conjugate; Breast cancer, Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant to supersede T-DM1 by using a cleavable linker and a more potent payload with a different mechanism of action. To determine the effect of one of these novel ADCs, SYD985, on tumors resistant to T-DM1, we developed several patient-derived models of resistance to T-DM1. Characterization of these models showed that previously described mechanisms—HER2 downmodulation, impairment of lysosomal function and upregulation of drug efflux pumps—account for the resistances observed, arguing that mechanisms of resistance to T-DM1 are limited, and most of them have already been described. Importantly, SYD985 was effective in these models, showing that the resistance to first generation ADCs can be overcome with an improved design., This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Fundación Mutua Madrileña, Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer. BM is supported by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). JZ is supported by a fellowship from China Scholarship Council (CSC). JA is supported by Institució Catalana de Recerca i Estudis Avançats.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation

  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Rius Ruiz, Irene|||0000-0002-6097-7572
  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Luque, Antonio
  • Fajardo, Carlos Alberto
  • Gros, Alena
  • Klein, Christian|||0000-0001-7594-7280
  • Arribas, Joaquín V|||0000-0002-0504-0664
Immunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfailingly eliminate the latter, provided that inhibitory factors are in check. T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) offer an opportunity to test this assumption. Using TCB and CARs directed against HER2, here we show that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes. The kinase JAK2, which transduces the signal initiated by interferon-gamma, is a component repeatedly disrupted in several independently generated resistant models. Our results unveil a seemingly widespread strategy used by cancer cells to resist clearance by redirected lymphocytes. In addition, they open the possibility that long-term inhibition of interferon-gamma signaling may impair the elimination phase of immunoediting and, thus, promote tumor progression. Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic disruption of interferon-gamma signalling, including downregulation of JAK2, confers resistance to T-cell mediated cytotoxicity
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • Adam-Artigues, Anna|||0000-0002-4257-8535
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Cervera Vidal, Raimundo|||0000-0002-8213-4058
  • Tormo, Eduardo
  • Hernando Davalillo, Cristina
  • Martínez Martínez, María Teresa|||0000-0003-1312-3555
  • Carbonell Asins, Juan Antonio|||0000-0002-8449-5674
  • Simón, Soraya
  • Poveda Ferriols, Jesús Manuel|||0000-0002-9785-0997
  • Moragón, Santiago|||0000-0001-6490-6977
  • Zazo, Sandra
  • Martínez, Débora
  • Rovira, Ana|||0000-0003-1301-2599
  • Burgués, Octavio|||0000-0002-2471-5516
  • Rojo, Federico|||0000-0001-9989-0290
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Bermejo, Begoña
  • Lluch, Ana|||0000-0003-2766-407X
  • Prat, Aleix|||0000-0003-2377-540X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Eroles, Pilar|||0000-0003-2708-6206
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer. AXL is a prognostic biomarker and a potential therapeutic target to restore trastuzumab response in HER2 + breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Nadal-Serrano, Mercedes|||0000-0002-1299-495X
  • Lalinde-Gutiérrez, Marta|||0000-0002-9858-8775
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Morancho, Beatriz|||0000-0003-3369-8647
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Gandullo-Sánchez, Lucía|||0000-0002-7841-230X
  • Pandiella, Atanasio|||0000-0002-4704-8971
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Dijcks, Fred A.|||0000-0002-6023-9422
  • Dokter, Wim .H.A.
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression. SIGNIFICANCE: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer

  • Palafox, Marta|||0000-0002-1762-3250
  • Monserrat, Laia|||0000-0002-8802-3033
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ibrahimi, Nusaibah|||0000-0003-4537-0323
  • Kannan, Srinivasaraghavan|||0000-0002-9539-5249
  • Mina, Leonardo
  • Herrera-Abreu, Maria Teresa
  • Òdena, Andreu|||0000-0003-1529-880X
  • Sánchez Guixé, Mònica|||0000-0002-9430-4413
  • Capelán, Marta
  • Azaro, Analía
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Grueso, Judit|||0000-0003-1093-7940
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Su, Faye
  • Lin, Kui
  • Clarke, Robert B.|||0000-0001-5407-3123
  • Caldas, Carlos|||0000-0003-3547-1489
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Michiels, Stefan|||0000-0002-6963-2968
  • García-Sanz, Alicia
  • Turner, Nicholas C.|||0000-0001-8937-0873
  • Prat, Aleix|||0000-0003-2377-540X
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Verma, Chandra S.
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Arnedos, Monica
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Serra, Violeta|||0000-0001-6620-1065
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra, Violeta|||0000-0001-6620-1065
  • Wang, Anderson T.|||0000-0002-3571-5095
  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Polanska, Urszula|||0000-0003-1017-594X
  • Palafox, Marta|||0000-0002-1762-3250
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Jones, Gemma|||0000-0002-7567-681X
  • Lai, Zhongwu|||0000-0002-1506-8222
  • Armenia, Joshua|||0000-0002-9005-7769
  • Michopoulos, Filippos|||0000-0002-3667-6147
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Brough, Rachel|||0000-0002-1862-7130
  • Gulati, Aditi|||0000-0001-7476-2524
  • Pettitt, Stephen|||0000-0003-3313-3857
  • Bulusu, Krishna C.|||0000-0002-5092-6640
  • Nikkila, Jenni|||0000-0003-1380-8781
  • Wilson, Zena|||0000-0001-8811-4069
  • Hughes, Adina|||0000-0002-5711-627X
  • Wijnhoven, Paul W.G.|||0000-0002-5489-3006
  • Ahmed, Ambar|||0000-0002-5890-5035
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lau, Alan|||0000-0003-1055-9812
  • Critchlow, Susan|||0000-0002-4647-8988
  • Dougherty, Brian|||0000-0002-0093-1142
  • Caldas, Carlos|||0000-0003-3547-1489
  • Mills, Gordon|||0000-0002-0144-9614
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Forment, Josep V.|||0000-0002-7797-2583
  • Cadogan, Elaine|||0000-0002-9757-8305
  • Lord, Christopher J.|||0000-0002-3226-0515
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • O'Connor, Mark J.|||0000-0003-1823-625X
PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. We analyzed breast and ovarian patientderived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

  • Nadal Serrano, Mercedes
  • Morancho Armisen, Beatriz
  • Escriva de Romaní Muñoz, Santiago Ignacio
  • Luque García, Antonio
  • Espinosa Bravo, Martin
  • Peg Camara, Vicente
  • Cortés Castan, Javier
  • Arribas López, Joaquin Vicente
  • Bernadó Morales, Cristina
  • Saura Manich, Cristina
  • Escorihuela Baez, Marta
T-DM1; Conjugat anticòs-fàrmac; Càncer de mama, T-DM1; Conjugado anticuerpo-fármaco; Cáncer de mama, T-DM1; Antibody-drug conjugate; Breast cancer, Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy, primary or acquired resistance frequently develops, particularly in advanced stages of the disease. Second generation ADCs targeting HER2 are meant to supersede T-DM1 by using a cleavable linker and a more potent payload with a different mechanism of action. To determine the effect of one of these novel ADCs, SYD985, on tumors resistant to T-DM1, we developed several patient-derived models of resistance to T-DM1. Characterization of these models showed that previously described mechanisms—HER2 downmodulation, impairment of lysosomal function and upregulation of drug efflux pumps—account for the resistances observed, arguing that mechanisms of resistance to T-DM1 are limited, and most of them have already been described. Importantly, SYD985 was effective in these models, showing that the resistance to first generation ADCs can be overcome with an improved design., This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Fundación Mutua Madrileña, Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer. BM is supported by a fellowship from PERIS (Departament de Salut, Generalitat de Catalunya). JZ is supported by a fellowship from China Scholarship Council (CSC). JA is supported by Institució Catalana de Recerca i Estudis Avançats.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.